For the Inventor, By the Inventor

Enter assignee name

Miami, FL, United States of America

Demerx, Inc.

USPTO Granted Patents = 37

% Expired Patents = 10.8

EPO Patents = 5

Trademarks = 3

Forward Citations = 266

Loading Chart...

Loading Chart...

12 inventors (with patents filed for the assignee):

Robert M Moriarty (17 out of 80 patents)

Deborah C Mash (17 out of 24 patents)

Richard D Gless (13 out of 28 patents)

4. Emeline Maillet (5 out of 7 patents)

5. Lawrence Friedhoff (5 out of 9 patents)

6. Holger Weis (3 out of 5 patents)

7. William C Schinzer (2 out of 3 patents)

8. Mark Kinch (1 out of 1 patent)

9. Richard D Gless, Jr (1 out of 1 patent)

10. Simon Mbua Ngale Efange (1 out of 1 patent)

11. Philip Sigel (1 out of 1 patent)

12. Pascal Goldschmidt (1 out of 1 patent)

Core Competencies:

Noribogaine

Cannabinoids

Iboga Alkaloids

Pain Management

Drug Addiction

Impulse Control Disorder

Migraine Treatment

Stereoselective Synthesis

Prodrugs

Blood Brain Barrier

Synthetic Voacangine

Phosphate Esters

37 patents: Sort by Forward Citations

1. 12653831 - Methods for the non-toxic treatment for opioid drug withdrawal combining noribogaine and cannabinoids (2026-06-16),

2. 11260059 - Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids (2022-03-01),

3. 11197866 - Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids (2021-12-14),

4. 11077118 - Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake (2021-08-03),

5. 9744174 - Method for noribogaine treatment in patients on methadone (2017-08-29),

6. 9617274 - Synthetic noribogaine (2017-04-11),

7. 9617265 - Noribogaine salt ansolvates (2017-04-11),

8. 9592239 - Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake (2017-03-14),

9. 9591978 - Methods and compositions for pre-screening patients for treatment with noribogaine (2017-03-14),

10. 9586954 - N-substituted noribogaine prodrugs (2017-03-07),

11. 9561233 - Use of ibogaine for the treatment of pain (2017-02-07),

12. 9561232 - Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use (2017-02-07),

13. 9550789 - Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them (2017-01-24),

14. 9549935 - Methods and compositions for treating migraines using noribogaine (2017-01-24),

15. 9469649 - Synthetic voacangine (2016-10-18),

Company Overview

Demerx, Inc. is a technology-driven company based in Miami, FL, specializing in the development and manufacturing of innovative solutions across various sectors. The organization focuses on advanced research in areas such as medical devices and health technology, aiming to enhance patient outcomes and streamline healthcare processes. With a commitment to quality and innovation, Demerx leverages cutting-edge technology to address complex challenges in the medical field, contributing to the evolution of healthcare solutions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

37 Patents

#19 in Miami, FL

#216 in Florida

#9,262 in US

#18,281 in the World

Miami, FL, United States of America

Demerx, Inc.

Forward Citations = 266

12 inventors:

Robert M Moriarty (17 out of 80 patents)

Deborah C Mash (17 out of 24 patents)

Richard D Gless (13 out of 28 patents)

4. Emeline Maillet (5 out of 7 patents)

5. Lawrence Friedhoff (5 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Demerx, Inc.. Retrieved from https://idiyas.com/company/demerx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…